Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Ribosome Profiling

Ribosome Profiling

Ribosome profiling or ribo-sequencing is a deep sequencing technique that produces a snapshot of active translation in a cell. It selectively sequences the mRNAs protected by ribosomes to get an insight into a cell’s translation landscape at any given point in time.
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Off-Label Sotatercept Use in Pediatric Pulmonary Arterial Hypertension: A Single-Center Retrospective Hemodynamic Study.

Pediatric cardiology·2026

Same author

Dramatic Remodeling of Hypoplastic Pulmonary Arteries by Pulmonary Valve Opening, Right Ventricular Outflow Stenting, and Aortopulmonary Collateral Lung Territory Incorporation.

Journal of the Society for Cardiovascular Angiography & Interventions·2026

Same author

Advancing IBD Management: A Literature Review on the Role of Non-Invasive Blood-Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment.

Clinical and translational science·2026

Same author

Utilization of Model-Informed Drug Development in Early Clinical Development: Case Study of a Hb Modulator for Treatment of Sickle Cell Disease.

CPT: pharmacometrics & systems pharmacology·2026

Same author

Integrating Patient Engagement into Clinical Pharmacology and Pharmacometrics: Bringing the Patient Voice into Data-Driven Science.

Clinical pharmacology and therapeutics·2026

Same author

Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development.

Clinical pharmacology and therapeutics·2025

Search research articles

Related Experiment Video

Updated: May 6, 2026

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

Model-Informed Drug Development Applications and Opportunities in mRNA-LNP Therapeutics.

Jiawei Zhou¹, Rohit Rao², Monica E Shapiro²

¹Pfizer Inc, Groton, Connecticut, USA.

Clinical Pharmacology and Therapeutics

|March 14, 2025

Summary

Model-Informed Drug Development (MIDD) aids mRNA-LNP therapeutics by integrating data for safety and efficacy evaluation. This approach enhances clinical development by leveraging various modeling techniques and sharing knowledge across therapeutic modalities.

More Related Videos

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

Author Spotlight: Enhancing Lipid Nanoparticle Formation Through Turbulent Mixing in Confined Geometries

Author Spotlight: Enhancing Lipid Nanoparticle Formation Through Turbulent Mixing in Confined Geometries

Published on: August 23, 2024

Related Experiment Videos

Last Updated: May 6, 2026

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

Author Spotlight: Enhancing Lipid Nanoparticle Formation Through Turbulent Mixing in Confined Geometries

Author Spotlight: Enhancing Lipid Nanoparticle Formation Through Turbulent Mixing in Confined Geometries

Published on: August 23, 2024

Area of Science:

Pharmacology and Therapeutics
Biotechnology
Computational Biology

Background:

Lipid nanoparticles (LNPs) encapsulating mRNA have transformed vaccine development, including for COVID-19 and cancer.
Clinical progression of mRNA-LNP therapeutics is hindered by complex mechanisms and limited clinical data.
Model-Informed Drug Development (MIDD) offers a framework to address these challenges.

Purpose of the Study:

To review current applications of MIDD in the clinical development of mRNA-LNP therapeutics using in vivo data.
To compare clinical pharmacology across mRNA, small interfering RNA, and adeno-associated virus-based gene therapies.
To explore potential knowledge sharing of MIDD strategies between these therapeutic classes.

Main Methods:

Review of various modeling and simulation techniques, including quantitative systems pharmacology (QSP), physiologically based pharmacokinetics (PBPK), and mechanistic/population pharmacokinetics/pharmacodynamics (PK/PD).
Model-based meta-analysis (MBMA) is also discussed.
Comparative analysis of clinical pharmacology and MIDD applications across different nucleic acid-based therapeutics.

Main Results:

MIDD integrates diverse data to evaluate safety and efficacy throughout the development lifecycle.
Specific modeling approaches like QSP, PBPK, and PK/PD are applicable to mRNA-LNP therapeutics.
Potential exists for synergistic application of MIDD knowledge across mRNA, siRNA, and AAV-based therapies.

Conclusions:

MIDD is a crucial tool for advancing mRNA-LNP therapeutic development.
Applying MIDD enhances the evaluation of safety and efficacy for these complex therapies.
Recognizing the value of MIDD is essential for stakeholders to optimize clinical progression.